Yaru Song

Gold nanoparticle‐enhanced chemiluminescence detection for CE

Introducing gold nanoparticles (AuNPs) to the running buffer further improved the sensitivity of luminol‐H2O2 chemiluminescence (CL) detection for CE. This has led to the development of sensitive CE‐CL assays of biomedically interesting compounds. Epinephrine and norfloxacin were taken as the model analytes. Epinephrine inhibited light emission from the AuNP‐catalyzed CL while norfloxacin enhanced it. The CE‐CL assays had detection limits of 6.9×10−9 M for epinephrine and 7.3×10−9 M for norfloxacin. It was noted that in the absence of AuNPs no CE‐CL analytical signal was produced by epinephrine at 4.0×10−5 M or norfloxacin at 1.5×10−3 M under similar experimental conditions. Fluorescence spectroscopic measurements showed that although the fluorescence excitation/emission maxima remained the same, the fluorescence lifetime of luminol increased significantly in the presence of AuNPs (τ2 increased from 8.49±0.12 to 9.18±0.047 ns in a two‐exponential fit), indicating that the excited states of luminol molecules were stabilized through the interaction between luminol molecules and AuNPs. Finally, quantitation of epinephrine and norfloxacin in biological samples such as human urine by using the present AuNP‐enhanced CE‐CL method was demonstrated.

D-Amino acids in rat brain measured by liquid chromatography/ tandem mass spectrometry

Previous work has established that D-amino acids including D-serine (D-Ser) and D-aspartic acid (D-Asp) fulfill specific biological functions in the brain. In this work, the levels and anatomical distribution of d-amino acids in rat brain were determined by using an advantageous liquid chromatography/tandem mass spectrometric analytical method. The study was focused on D-Ser, D-Asp, and D-glutamic acid (D-Glu) because of the significance of L-Asp, L-Glu, and D-Ser in the nervous system. Prenatal, postnatal pups, and 90-day old rats were studied. Results indicated that D-Asp and D-Ser occurred in rat brain at the microg/g tissue level. However, D-Glu was not detected (< 110 ng/g tissue). Throughout the developmental stages d-Asp content in rat brain decreased rapidly from 9.42% of total Asp in 5-day prenatal rats to an undetectable level (< 150 ng/g tissue) in 90-day old rats. In contrast, D-Ser level increased gradually throughout the developmental stages. D-Ser percentage (D-Ser/(D-Ser + L-Ser)) changed from 4.94% in 5-day prenatal rats to 13.7% in 90-day old rats. Regional levels of D-Ser were found to be significantly higher in cortex, striatum, and hippocampus than in thalamus. D-Ser was not detected in cerebellum (< 172ng/g tissue).

1-Benzyl-1,2,3,4-tetrahydroisoquinoline passes through the blood–brain barrier of rat brain: An in vivo microdialysis study

Previous work has established that 1-benzyl-1,2,3,4-tetrahydroisoquinoline (1-BnTIQ) causes a parkinsonian syndrome in rats. The present study reports the blood-brain barrier (BBB) permeability of 1-BnTIQ in freely moving rats with the aid of in vivo microdialysis-based measurements. The microdialysis probe was implanted in the frontal cortex of rat brain. Brain dialysate samples were analyzed using an HPLC-MS/MS assay. 1-BnTIQ, when administered i.p., dose-dependently appeared in brain extracellular fluid (ECF), reaching a maximum concentration after about 40 min. Two other tetrahydroisoquinoline derivatives, 1,2,3,4-tetrahydroisoquinoline (TIQ) and 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline [salsolinol (SAL)], served as positive and negative controls, respectively. The results confirmed an earlier report that SAL does not reach the brain after i.p. administration. In contrast, TIQ readily passed through the BBB. The brain dialysate concentration of 1-BnTIQ was about 24% that of TIQ when administered i.p. at the same dose. Both of them decreased quickly with a half-life of about 50 min.